Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations

Background and Purpose Currently, there are no licensed vaccines and limited antivirals for the treatment of COVID‐19. Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID‐19 patients. Additionally, in the United Kingdom, Brazil and Australia, nebulised unfrac...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of pharmacology Vol. 178; no. 3; pp. 626 - 635
Main Authors:	Tree, Julia A., Turnbull, Jeremy E., Buttigieg, Karen R., Elmore, Michael J., Coombes, Naomi, Hogwood, John, Mycroft‐West, Courtney J., Lima, Marcelo A., Skidmore, Mark A., Karlsson, Richard, Chen, Yen‐Hsi, Yang, Zhang, Spalluto, Cosma Mirella, Staples, Karl J., Yates, Edwin A., Gray, Elaine, Singh, Dave, Wilkinson, Tom, Page, Clive P., Carroll, Miles W.
Format:	Journal Article
Language:	English
Published:	England Blackwell Publishing Ltd 01.02.2021 John Wiley and Sons Inc
Subjects:	ACE2 Angiotensin-converting enzyme 2 Angiotensin-Converting Enzyme 2 - metabolism Animals Anticoagulants Antiviral activity Antiviral agents Antiviral Agents - pharmacology Antiviral drugs Chlorocebus aethiops COVID-19 COVID-19 Drug Treatment Heparin Heparin - metabolism Heparin - pharmacology Heparin - therapeutic use Heparin, Low-Molecular-Weight - pharmacology Infectivity LMWH nebulised Patients Protein Binding - drug effects Proteins Research Paper Research Papers SARS-CoV-2 - growth & development SARS‐CoV‐2 Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - metabolism Spike protein Therapeutic applications UFH Viral Plaque Assay Australia COVID-19 heparin nebulised LMWH SARS-CoV-2 UFH
ISSN:	0007-1188, 1476-5381, 1476-5381
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!